Two distinct therapeutic approaches are emerging to combat cellular senescence, a key driver of aging. Senolytics work by selectively eliminating senescent cells that accumulate in tissues over time, while senomorphics take a different approach by modulating the harmful inflammatory secretions of these cells without killing them. Both strategies target the senescence-associated secretory phenotype (SASP), which drives chronic inflammation and tissue dysfunction as we age. This represents a fundamental shift from treating individual age-related diseases to addressing their common underlying mechanism. The field has moved beyond purely theoretical concepts, with multiple compounds now progressing through preclinical and clinical testing phases. This dual-pronged approach offers flexibility in treatment strategies—complete removal versus functional modulation of problematic cells. The therapeutic potential extends across numerous age-related conditions, from cardiovascular disease to neurodegeneration, suggesting these interventions could meaningfully extend healthspan rather than merely lifespan. However, the long-term safety profile of systematically clearing senescent cells remains to be established, particularly regarding potential effects on wound healing and immune function where some senescent cell functions may be beneficial.